← Back to Screener
Citius Oncology, Inc. Common Stock (CTOR)
Price$0.79
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-45.31%
Price vs S&P 500 (4W)-20.52%
VGM Score26.20
Market Capitalization$74.20M
All Metrics
Book Value / Share (Quarterly)$0.38
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.18
Price vs S&P 500 (YTD)-31.13%
EPS (TTM)$-0.47
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-0.47
EPS (Annual)$-0.34
ROI (Annual)-50.88%
Cash / Share (Quarterly)$0.03
ROA (Last FY)-24.53%
EBITD / Share (TTM)$-0.47
Cash Flow / Share (Annual)$-0.07
P/B Ratio2.10x
P/B Ratio (Quarterly)1.55x
Net Interest Coverage (TTM)-129.49x
ROA (TTM)-42.16%
EPS Incl Extra (Annual)$-0.34
Current Ratio (Annual)0.56x
Quick Ratio (Quarterly)0.06x
3-Month Avg Trading Volume0.21M
52-Week Price Return-10.34%
52-Week High$6.19
EPS Excl Extra (Annual)$-0.34
26-Week Price Return-29.38%
Quick Ratio (Annual)0.08x
13-Week Price Return-26.79%
Total Debt / Equity (Annual)0.08x
Current Ratio (Quarterly)0.50x
Enterprise Value$75.37M
Cash / Share (Annual)$0.05
3-Month Return Std Dev96.88%
ROE (Last FY)-55.19%
EPS Basic Excl Extra (Annual)$-0.34
Total Debt / Equity (Quarterly)0.11x
EPS Incl Extra (TTM)$-0.47
ROI (TTM)-91.35%
Revenue / Share (Annual)$0.00
Forward P/E10.18x
Price vs S&P 500 (52W)-38.54%
Year-to-Date Return-20.20%
5-Day Price Return-4.99%
EPS Normalized (Annual)$-0.34
Month-to-Date Return-9.31%
EBITD / Share (Annual)$-0.32
LT Debt / Equity (Annual)0.08x
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$-0.47
P/B Ratio (Annual)3.78x
Book Value / Share (Annual)$0.54
Price vs S&P 500 (13W)-36.54%
Beta3.36x
P/FCF (Annual)587.25x
Revenue / Share (TTM)$0.06
ROE (TTM)-99.47%
52-Week Low$0.49
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q2 26-0.27est. -0.01
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CTORCitius Oncology, Inc. Common Stock | — | — | D | $0.79 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Citius Oncology is a biopharmaceutical company developing targeted cancer therapies through lower-risk approaches, including new formulations and expanded indications for approved drugs. The company leverages intellectual property and regulatory exclusivity to accelerate market entry while serving key cancer centers.